Advancing Precision Psychiatry: Insights from the Neuropsychiatry Congress

Event recap

The 2026 CSF Society and Clinical Neurochemistry Conference brought together a diverse community of students, researchers, clinicians, and industry experts focused on advancing biomarker discovery for neurological disorders. Discussions spanned neurodegenerative and inflammatory diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), highlighting how biomarker research is increasingly shaping the future of precision neurology.

While scientific innovation remained front and center, one message resonated throughout the meeting: the field is entering a new era where the challenge is disentangling disease complexity with a systems-biology view beyond established markers, while also effectively translating emerging biomarker candidates into clinical practice.

Takeaway 1

Blood-based biomarkers enter the next phase

The growing success of blood-based biomarkers (BBMs), particularly pTau217, alongside recent regulatory approvals, has generated significant optimism across the neurology community. These advances have established blood testing as a powerful tool for identifying Alzheimer’s disease pathology, with adoption underway in memory clinics across Europe, Asia, and North America.

However, the conference highlighted that the next major challenge lies in broader clinical implementation. Expanding the use of BBMs into primary care settings will require a deeper understanding of how comorbidities influence biomarker levels, as well as clear clinical guidelines for interpretation and use.

Researchers emphasized the importance of addressing questions around intermediate biomarker results, which continue to vary across research cohorts and remain poorly characterized in routine clinical practice. Establishing evidence-based frameworks for managing these cases will be critical to avoid both overdiagnosis of Alzheimer’s disease and missed diagnoses of alternative neurological conditions.

Despite these challenges, accumulating evidence suggests that blood-based biomarkers could play a pivotal role in enabling biological staging and more personalized patient management in Alzheimer’s disease.

Takeaway 2

Expanding biomarker frameworks beyond neurodegeneration

The impact of biomarker-driven approaches may extend far beyond traditional neurodegenerative diseases.

Several presentations highlighted how biological frameworks are increasingly being adopted in psychiatric and mental health disorders, where symptoms often overlap with neurodegenerative conditions. This creates opportunities to develop biomarkers that can support more accurate diagnosis, monitor disease progression, and assess therapeutic response.

The concept of companion diagnostics and predictive biomarkers was discussed, with growing interest in identifying molecular signatures that can help stratify patients, predict outcomes, and guide precision treatment strategies across a broader spectrum of neurological and psychiatric disorders.

Takeaway 3

Complementary windows into Alzheimer’s disease biology

While blood-based biomarkers continue to gain momentum, speakers reinforced the importance of viewing them as part of a broader diagnostic ecosystem.

PET imaging, cerebrospinal fluid (CSF) biomarkers, and plasma biomarkers each capture distinct aspects of Alzheimer’s disease pathology. Rather than competing approaches, they serve as complementary reference standards that together provide a more complete picture of disease biology.

Among emerging markers, plasma eMTBR-tau243 received considerable attention as a promising addition to the Alzheimer’s disease biomarker landscape. Unlike markers that primarily reflect amyloid pathology, eMTBR-tau243 appears to increase alongside tau aggregation, potentially offering a closer link to cognitive symptoms and disease progression.

Takeaway 4

Looking beyond established markers

A recurring theme throughout the conference was the need to move beyond established Alzheimer’s disease biomarkers and better understand the biological processes driving disease heterogeneity.

Particular attention was given to biomarkers associated with synaptic dysfunction, or synaptopathy, which is increasingly recognized as a key contributor to cognitive decline.

Several promising candidates were highlighted:

• SNAP25, which may serve as an early marker of amyloid accumulation and support prognostic assessment.
• NPTX2, which appears informative in prodromal Alzheimer’s disease and may provide insights beyond traditional measures of neurodegeneration.
• Neurogranin and beta-synuclein, both of which continue to demonstrate potential as markers of synaptic integrity and dysfunction.

Emerging evidence suggests that Alzheimer’s disease involves complex, multidirectional interactions among amyloid pathology, synaptic dysfunction, glial activation, and neurodegeneration. Biomarkers that capture these interconnected processes may help researchers better understand disease mechanisms, characterize patient heterogeneity, improve diagnosis, and evaluate novel therapies targeting synaptic health.

Takeaway 5

Understanding the role of glial biology

The conference also highlighted increasing interest in glial biology and the need to expand research beyond established markers such as GFAP.

Rather than acting solely as passive responders to amyloid accumulation, astrocytes and other glial cells are now understood to be active participants in disease progression. Researchers discussed several emerging candidates, including syndecan-4, a marker associated with reactive astrocytes and LAMA4, which has been shown to be upregulated in astrocytes under neurodegenerative conditions.

Further investigation of these markers may help uncover previously underappreciated pathways contributing to neuronal dysfunction and cognitive decline.

Takeaway 6

Proteomics and disease monitoring in multiple sclerosis

Beyond Alzheimer’s disease, multiple sclerosis remained an important area of focus.

Researchers emphasized the value of longitudinal proteomic profiling to better understand the mechanisms underlying demyelination and disease progression. By capturing temporal changes in protein expression, proteomics offers the potential to improve patient monitoring, identify new therapeutic targets, and support more personalized disease management strategies.

Takeaway 7

The future of precision neurology

One conclusion emerged clearly from CSF Society 2026: the future of neurology will depend not only on validating established biomarkers, but also on discovering and understanding new biological signals that can capture disease complexity.

As the field moves toward precision medicine, proteomics is uniquely positioned to accelerate discovery across neurodegenerative, neuroinflammatory, and psychiatric disorders – providing deeper insights into disease mechanisms, patient stratification, and treatment response.